LEX Diagnostics Receives FDA 510(k) Clearance for Ultra-Fast Point-of-Care PCR System
核心洞察
LEX Diagnostics (搜索) has received FDA 510(k) clearance and CLIA waived status for its VELO system (搜索), an ultra-fast point-of-care molecular diagnostics platform that delivers PCR results in under ten minutes.
The system supports multiplex testing for key respiratory pathogens including Influenza A (搜索), Influenza B (搜索), and COVID-19 (搜索), with results delivered in six to ten minutes directly from a swab sample.
The proprietary cartridge-based design eliminates external liquid handling requirements and integrates easily into various clinical settings including primary care, urgent care clinics, and pharmacies.
LEX Diagnostics (搜索), a Cambridge-based molecular diagnostics company, has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting 510(k) clearance and CLIA waived status for its VELO system (搜索). The ultra-fast point-of-care molecular diagnostics platform represents a breakthrough in rapid pathogen detection, delivering highly sensitive PCR results for key respiratory pathogens directly from a swab sample in under ten minutes.
The FDA clearance marks a pivotal advancement in point-of-care testing technology, addressing the critical need for rapid, accurate diagnostic results in clinical settings. "This groundbreaking achievement is a result of several years of innovation, problem solving, and dedication to our mission to make molecular diagnostics faster, simpler, and more accessible," said Ed Farrell, Chief Executive Officer of LEX Diagnostics (搜索).
Revolutionary Speed and Accuracy
The VELO system (搜索) is precision engineered to deliver PCR results in six to ten minutes, a dramatic improvement over traditional laboratory-based testing timelines. The platform supports multiplex testing for key respiratory pathogens, including Influenza A (搜索), Influenza B (搜索), and COVID-19 (搜索), enabling comprehensive respiratory pathogen screening in a single test.
The system's proprietary cartridge-based design eliminates the need for external liquid handling, promoting ease of use and reliability across diverse clinical environments. This streamlined approach bridges the gap between laboratory-quality accuracy and point-of-care accessibility, enabling healthcare professionals to make informed clinical decisions significantly faster than current standard practices.
Clinical Integration and Commercial Readiness
The VELO system (搜索) is designed to integrate seamlessly into point-of-care clinical workflows across multiple healthcare settings, including primary care facilities, urgent care clinics, pharmacies, physician office laboratories, and decentralized acute care environments. This versatility positions the platform to address diagnostic needs across the healthcare continuum.
LEX Diagnostics (搜索) completed clinical studies in the United States with the VELO system (搜索) and the Influenza/COVID assay during the 2024/2025 respiratory season, demonstrating the platform's real-world performance and clinical utility. The company anticipates beginning U.S. commercial activities in 2026, following the successful regulatory clearance.
Transforming Point-of-Care Diagnostics
"We believe our VELO system (搜索) will redefine point-of-care testing by equipping healthcare providers with lab-quality results in a few minutes," Farrell explained. "This improved point-of-care workflow will enable faster clinical decisions and improved patient outcomes without compromising quality — an achievement that will set us apart in the marketplace."
The CLIA waived status further enhances the system's accessibility, allowing use in settings with basic laboratory oversight requirements. This regulatory designation recognizes the platform's user-friendly design and reliable performance characteristics.
LEX Diagnostics (搜索), a TTP Group (搜索) company headquartered in Cambridgeshire, United Kingdom, has developed its proprietary ultra-fast thermal cycling technology to transform molecular diagnostics. The VELO system (搜索) represents the culmination of the company's commitment to advancing point-of-care testing with accurate, timely, and clinically actionable results that empower healthcare professionals to deliver improved patient care.